THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio & Medicine

February 20, 2019
Yuhan’s sales hit W1.5tr in 2018

Korean pharmaceutical company Yuhan announced on Feb. 20 that its sales reached 1.5 trillion won (US$1.3 billion) last year, up 4 percent from the previous year. Yuhan has now become the first Korean pharmaceutical company to post annual sales exceeding 1.5 trillion won. Three other firms -- Kolma...
February 19, 2019
JW Life Science to giveW8b dividends

Koreas intravenous solution maker JW Life Science announced on Feb. 18 that it has decided to give 500 won (US$0.44) dividend per share, which amounts to around 7.91 billion won in total. Established in 1994, the firm is a subsidiary of JW Holdings which holds around 43.1 percent stake in Korea’s...
February 15, 2019
Kwangdong reorganizes biz after crashing and burning overseas

Korean drug maker Kwangdong Pharmaceutical, which has been focusing on diversifying its business portfolio, appears to be making attempts at a turnaround amid its slumping global business. The Korean company’s American dream, which started in 2015 through establishing Kwangdong USA, to sell its b...
February 15, 2019
SK Biopharmaceuticals signs US$530m licensing deal for Cenobamate in Europe

SK Biopharmaceuticals, the new drug development subsidiary of South Korean conglomerate SK Group, announced on Feb. 14 that it had signed a deal worth US$530 million with Swiss drug company Arvelle Therapeutics to commercialize its drug candidate Cenobamate in Europe. Cenobamate is the Korean comp...
February 14, 2019
CJ Healthcare signs US$84m deal for exporting Tegoprazan

CJ Healthcare announced on Feb. 13 that it has signed a deal worth US$84 million with Mexico-based Laboratorios Carnot to exclusively supply its drug Tegoprazan for the next 10 years. Tegoprazan, which is a treatment for gastroesophageal reflux disease, is the first novel drug developed by CJ Heal...
February 13, 2019
Genexine, SCM acquire US biotech firm for W12.5b

Korean firms Genexine and SCM Life science announced on Feb. 13 that they have jointly acquired US biotech firm Argos Therapeutics for around 12.5 billion won (US$ 11.14 million) through an auction. Established in 1997, Argos, located in North Carolina, was listed on NASDAQ until 2018. The firm ...
February 13, 2019
Bridge Biotherapeutics hopes to go public this year

Korean biotech firm Bridge Biotherapeutics is aiming to get listed on the second-tier KOSDAQ market this year, having picked KB Securities and Daishin Securities as its IPO manager, according to company sources on Feb. 13. “We have two new candidates that are undergoing clinical trials this year,...
February 11, 2019
Samsung Bioepis, C-Bridge Capital to speed up expansion in China

Korean drug developer Samsung Bioepis announced Feb. 11 that it has inked a partnership with Chinese private equity firm C-Bridge Capital. “We expect C-Bridge to be a great partner for our business in China,” Samsung Bioepis CEO Ko Han-sung said in a statement. Established in 2014, C-Bridge Cap...
February 08, 2019
Daewoong Pharma shares soar after FDA approval

Shares of Daewoong Pharmaceutical have been rallying since the company announced on Jan. 1 that its botulinum toxin Nabota received marketing authorization from the US Food and Drug Administration. Korea’s leading drug maker and its US partner Evolus plan to start selling Nabota under the name Je...
February 08, 2019
Voronoi plans to raise W100b before IPO

New drug developer Voronoi is seeking to raise fresh funds worth 100 billion won (US$89 million) ahead of a potential initial public offering, according to news reports on Feb. 8. Established in 2015, Voronoi is currently developing treatments for lung cancer, brain cancer, Parkinson’s disease an...
February 01, 2019
Daewoong Pharma CEO refutes rivals’ claims on Nabota

Daewoong Pharmaceutical Chairman Jeon Seung-ho on Feb. 1 strongly refuted allegations by its rivals that it stole manufacturing secrets to develop botulinum toxin Nabota. The announcement came after a Bloomberg report that Allergan and partner Medytox have filed a complaint with the International ...
February 01, 2019
KyungDong Pharma invests W1b in biotech fund

[THE INVESTOR] Korean drug maker KyungDong Pharmaceutical said on Feb. 1 that it has invested 1 billion won (US$894,694) in a biotech and health care related startup focused fund led by venture capital firm DAYLI Partners DAYLI Partners is a venture capital firm that has been focusing on investin...
January 31, 2019
Rokit secures W11b from Korean investors

[THE INVESTOR] Korean 3D bio-printer maker Rokit has secured 11 billion won (US$9.89 million) in funding from KB Investment, Korea Development Bank and DAYLI Partners, according to sources on Jan.31. The three investors have reportedly bought around 1.05 million won worth of redeemable convertibl...
January 30, 2019
Samsung Bioepis posts sales of US$545m in Europe in 2018

[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis saw its accumulated sales in the European market hit US$545.2 million last year, data showed on Jan. 30. Sales of three biosimilar products -- Benepali, Flixabi and Imradli -- surged 44 percent on-year in 2018, according to the data pro...
January 28, 2019
Genosco gears up for IPO

[THE INVESTOR] Genosco, a US-based subsidiary of Korean bio company Oscotec, is gearing up to go public, according to industry sources on Jan. 28. The company recently sent out a request for proposals to several major securities firms, including NH Investment & Securities and Samsung Securities. ...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |
CEO : Jeon Chang-hyeop |
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |
Title : The Investor |
Date of registration : 2016.06.21 |
Date of issue : 2016.06.21

Publisher. Editor : Jeon Chang-hyeop |
Chief Privacy Officer & Juvenile Protection Manager : Ahn Sung-mi |
T +82-2-727-0114

FAMILY SITE GO

Company Registration No. 104-81-06004 |
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |
Business info |
Gov’t registration No. Seoul 아04099